Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 10.46% is in line with its 5-year average of 11.49%, around the middle of its 5-year range (5.92%–18.23%).
12.25% below its 12-month average of 11.92%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.68%.
RETURN ON ASSETS (ROA)
10.46%
RETURN ON ASSETS (ROA) AVG TTM
11.92%
RETURN ON ASSETS (ROA) AVG 3Y
11.16%
RETURN ON ASSETS (ROA) AVG 5Y
11.49%
RETURN ON ASSETS (ROA) AVG 10Y
10.18%
RETURN ON ASSETS (ROA) AVG 15Y
9.40%
RETURN ON ASSETS (ROA) AVG 20Y
9.42%
CURRENT VS TTM AVG
-12.25%
CURRENT VS 3Y AVG
-6.23%
CURRENT VS 5Y AVG
-8.99%
CURRENT VS 10Y AVG
+2.73%
CURRENT VS 15Y AVG
+11.26%
CURRENT VS 20Y AVG
+11.00%
SECTOR MEDIAN · HEALTHCARE
4.94%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+111.74%
vs the sector median at left
Novartis AG
Market Cap
$268.00B
Return on Assets (ROA)
10.46%
TTM Avg
11.92%
3Y Avg
11.16%
5Y Avg
11.49%
Market Cap
$243.33B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$242.11B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$332.94B
Return on Assets (ROA)
12.78%
TTM Avg
10.46%
3Y Avg
11.93%
5Y Avg
13.23%
Market Cap
$337.74B
Return on Assets (ROA)
4.56%
TTM Avg
4.36%
3Y Avg
6.27%
5Y Avg
6.84%
Market Cap
$356.40B
Return on Assets (ROA)
2.44%
TTM Avg
13.98%
3Y Avg
10.40%
5Y Avg
10.28%
Market Cap
$179.47B
Return on Assets (ROA)
-6.56%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$168.71B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novartis AG (NVS) | $268.00B | 10.46% | 11.92% | 11.16% | 11.49% |
| AstraZeneca PLC (AZN)vs › | $243.33B | 9.03% | 7.88% | 6.26% | 4.99% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $242.11B | 6.17% | 6.31% | 6.46% | 7.20% |
| Amgen Inc. (AMGN)vs › | $217.52B | 9.14% | 6.48% | 7.48% | 8.52% |
| Roche Holding AG (RHHBY)vs › | $332.94B | 12.78% | 10.46% | 11.93% | 13.23% |
| UnitedHealth Group Incorporated (UNH)vs › | $337.74B | 4.56% | 4.36% | 6.27% | 6.84% |
| Merck & Co., Inc. (MRK)vs › | $356.40B | 2.44% | 13.98% | 10.40% | 10.28% |
| Gilead Sciences, Inc. (GILD)vs › | $179.47B | -6.56% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT)vs › | $168.71B | 4.97% | 11.99% | 10.28% | 9.45% |
| Novo Nordisk A/S (NVO)vs › | $165.72B | 19.90% | 20.27% | 22.54% | 48.60% |
ROA
10.5%
ROE
30.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 12.16% |
| 2024-12-31 | 11.68% |
| 2023-12-31 | 14.86% |
| 2022-12-31 | 5.92% |
| 2021-12-31 | 18.23% |
| 2020-12-31 | 6.11% |
| 2019-12-31 | 9.91% |
| 2018-12-31 | 8.66% |
| 2017-12-31 | 5.79% |
| 2016-12-31 | 5.16% |
| 2015-12-31 | 13.52% |
| 2014-12-31 | 8.14% |
| 2013-12-31 | 7.27% |
| 2012-12-31 | 7.46% |
| 2011-12-31 | 7.61% |
| 2010-12-31 | 7.94% |
| 2009-12-31 | 8.80% |
| 2008-12-31 | 10.47% |
| 2007-12-31 | 15.83% |
| 2006-12-31 | 10.55% |
| 2005-12-31 | 10.62% |
| 2004-12-31 | 9.85% |
| 2003-12-31 | 9.62% |
| 2002-12-31 | 10.47% |
| 2001-12-31 | 9.52% |
| 2000-12-31 | 12.59% |
| 1999-12-31 | 10.15% |
| 1998-12-31 | 10.86% |
